Testosterone replacement therapy does not appear to cause permanent obstructive sleep apnea in clinical trials, though it can worsen overnight oxygen drops during the first several weeks.
At Longevity Benchmark, we evaluate clinical trial publications to help you understand what hormone research demonstrates about breathing health. A primary trial documented an early drop in oxygen levels that resolved completely by eighteen weeks.
The Verdict
Trial Evidence on Overnight Oxygen Desaturation
Randomised trial data demonstrate that testosterone therapy produces a temporary worsening in nocturnal oxygen desaturation rather than a persistent respiratory decline.
In a trial published in Clinical Endocrinology, Hoyos and colleagues examined 67 obese men with severe obstructive sleep apnea over 18 weeks. Investigators assigned 33 men to intramuscular testosterone undecanoate and 34 men to placebo. At baseline, total testosterone averaged 13.2 nmol/L in the active arm and 13.4 nmol/L in the control group. Sleep studies occurred at weeks 0, 7, and 18.
At week 7, testosterone worsened the oxygen desaturation index by 10.3 events per hour compared to placebo (P=0.03). Time spent with oxygen saturation below 90% increased by 6.1% (P=0.01). By week 18, this early disparity disappeared. Testosterone did not alter the oxygen desaturation index (P=0.36) or nocturnal hypoxaemia (P=0.23) against placebo at the trial close. The researchers concluded that testosterone mildly worsens sleep-disordered breathing in a time-limited manner regardless of starting hormone concentrations.
Other clinical investigations evaluated ventilation and airway dimensions. In the Journal of Sleep Research, Killick and colleagues studied 21 obese men with apnea over 18 weeks. They found no significant difference in awake ventilatory chemoreflexes between groups at 6 or 18 weeks. Earlier research by Liu and colleagues in The Journal of Clinical Endocrinology & Metabolism evaluated 17 healthy men over 60 receiving high-dose testosterone injections. Their total and non-REM respiratory disturbance indices increased by approximately 7 events per hour. Total sleep time fell by about one hour, and nocturnal hypoxaemia increased by about 5 minutes. Acoustic reflectometry showed no narrowing of the upper airway, and the published record provides no verified anatomical cause for the change.
Broader cohorts show mixed statistical patterns. A 2025 study in the International Journal of Transgender Health tracked 22,745 transmasculine individuals on testosterone. Researchers observed a hazard ratio of 1.74 for obstructive sleep apnea compared to cisgender males. Earlier meta-analytic work presents a different picture. In The Journals of Gerontology, Series A, Calof and colleagues reviewed 19 randomised trials covering 651 testosterone-treated men and 433 control participants. They found that the frequency of sleep apnea did not differ significantly between groups. Currently, no systematic review or meta-analysis pools the direct effect of testosterone therapy on the apnea-hypopnea index.
The Impact of Obstructive Sleep Apnea on Testosterone
Severe obstructive sleep apnea correlates with lower circulating testosterone levels, but correcting nocturnal airway collapse does not reliably restore hormone production.
In a 2022 meta-analysis published in Andrology, Su and colleagues evaluated 18 studies including 1,823 men. Serum testosterone showed an inverse association with sleep apnea (standardised mean difference, or SMD, -0.76). This association persisted after adjusting for age and body mass index (SMD -0.80). The drop remained statistically significant only in severe obstructive sleep apnea (SMD -1.21), with no significant suppression in mild or moderate cases.
A 2023 meta-analysis in Sleep and Breathing pooled 24 case-control studies covering 1,389 male patients and 845 controls. Men with sleep apnea had significantly lower serum total testosterone than controls (SMD -0.97). In women, researchers observed no significant difference. If you experience fatigue or signs of low testosterone, impaired nocturnal breathing may accompany that hormonal deficit.
Mechanical treatment of the airway does not reverse these endocrine deficits. Continuous positive airway pressure (CPAP) pneumatically splints the airway during sleep. In the Journal of Clinical Sleep Medicine, Cignarelli and colleagues reviewed 12 studies involving 388 patients. CPAP use showed no significant change in total testosterone (mean difference 1.08; P=0.18). The authors noted that their review does not support a direct interaction between apnea and circulating testosterone. Earlier work by Zhang and colleagues in PLOS ONE analysed 232 men across 7 studies. Total testosterone showed no change before and after CPAP therapy (P=0.558). Airway therapy protects oxygenation, but it does not resolve hypogonadism on a men's hormone panel.
Endocrine Society Recommendations on Severe Apnea
Clinical guidelines advise against initiating testosterone therapy in men who have untreated severe obstructive sleep apnea.
The Endocrine Society published its clinical practice guideline in 2018. The guideline explicitly recommends against testosterone therapy in men with untreated severe obstructive sleep apnea. It lists this restriction alongside breast or prostate cancer, palpable prostate nodules, and PSA levels exceeding 4 ng/mL. Other conditions include uncontrolled heart failure, myocardial infarction or stroke within the last 6 months, thrombophilia, and elevated hematocrit.
The restriction specifies untreated severe disease. Diagnostic thresholds from the American Academy of Sleep Medicine (AASM) define this category. A clinical sleep evaluation measures respiratory disruptions using the apnea-hypopnea index (AHI). Mild sleep apnea involves 5 to 15 events per hour of sleep. Moderate sleep apnea spans 15 to 30 events per hour. Severe sleep apnea requires more than 30 events per hour of sleep.
The Endocrine Society guideline does not include mild or moderate apnea in its list of restrictions. If you review your own sleep apnea test results, your AHI score categorizes your breathing severity. Only a licensed physician can determine how guideline restrictions apply to your personal diagnostic history.
Red Blood Cell Elevation and Overlapping Hematocrit Concerns
Testosterone therapy stimulates red blood cell production, creating a secondary monitoring requirement that overlaps with sleep-disordered breathing.
The FDA label for generic testosterone cypionate notes that androgens stimulate red blood cells by enhancing erythropoietic stimulation factor. In a meta-analysis in The Journals of Gerontology, Series A, Calof and colleagues examined adverse events across 19 trials. Men receiving testosterone were nearly four times as likely to develop a hematocrit above 50% compared to placebo (odds ratio 3.69). Hematocrit elevation emerged as the most frequent adverse event in that pooled analysis.
Chronic nocturnal oxygen desaturation also prompts the body to produce additional red blood cells. Each condition pushes red blood cell count upward through separate biological triggers. No published clinical trial quantifies the additive hematocrit rise in patients with both obstructive sleep apnea and testosterone therapy.
Professional protocols outline clear stopping criteria for managing elevated readings. The Endocrine Society defines erythrocytosis as a hematocrit exceeding 54%. Its guideline recommends checking hematocrit before treatment and again between 3 and 12 months later. If levels surpass 54%, the guideline advises clinicians to withhold testosterone until hematocrit normalizes, then resume at a lower dose. Our analysis of high hematocrit on TRT explains how clinics manage this threshold.
Formulation Differences in Hematocrit Elevation
Different testosterone formulations produce variable increases in red blood cell concentration.
In 2022, researchers published a Bayesian network meta-analysis in The Journal of Urology, the American Urological Association's journal. The investigation evaluated 29 placebo-controlled randomised trials involving 3,393 men. Researchers measured mean hematocrit changes across five distinct delivery methods against placebo.
Short-acting intramuscular injections generated a substantially larger hematocrit increase than transdermal patches. However, these 29 randomised trials did not deliberately enrol men with obstructive sleep apnea. The study evaluated delivery methods in general hypogonadal cohorts rather than sleep-disturbed patients. Comparing delivery formats helps clarify how different preparations alter laboratory markers on TRT injections vs cream vs pellets.
| Formulation | Trials Analyzed | Mean Hematocrit Rise vs Placebo | 95% Confidence Interval |
|---|---|---|---|
| Oral testosterone undecanoate | Randomised trials | +4.3% | 0.7% to 8.0% |
| Intramuscular enanthate or cypionate | Randomised trials | +4.0% | 2.9% to 5.1% |
| Transdermal testosterone gel | Randomised trials | +3.0% | 1.8% to 4.3% |
| Intramuscular testosterone undecanoate | Randomised trials | +1.6% | 0.3% to 3.0% |
| Transdermal testosterone patch | Randomised trials | +1.4% | 0.2% to 2.6% |
Diagnostic Discrepancies in Home Sleep Apnea Testing
Home sleep apnea testing frequently underestimates the severity of sleep-disordered breathing because portable monitors record elapsed time rather than actual sleep duration.
The American Academy of Sleep Medicine diagnostic guideline notes that measurement error is inevitable in home testing compared to polysomnography. Portable monitors lack standard sleep staging sensors. Conventional home sensors cannot detect hypopneas associated solely with cortical arousals. Sensor dislodgement and variable signal quality further depress the calculated respiratory event index.
A 2025 study in the Journal of Clinical Sleep Medicine, indexed on PubMed Central, quantified this discrepancy using home-based polysomnography. Researchers found that mean total recording time exceeded mean total sleep time by 19% (457 minutes versus 383 minutes). Wakefulness after sleep onset accounted for 45% of that recording gap. Sleep latency contributed 30%, and morning wakefulness contributed 25%. Because wakeful minutes inflated the denominator, simulated home testing produced a mean AHI of 41 events per hour. That was 23% lower than the 53 events per hour recorded on home-based polysomnography.
Night-to-night biological variability adds another diagnostic challenge. The AASM guideline reviewed four studies comparing consecutive nights of polysomnography. Using an AHI treatment threshold of 15 or 20, two of those studies observed that 7.6% and 25% of participants crossed the threshold only on the second night. If you complete a home sleep apnea test, a single border reading may not capture your true baseline.
Prescription Drug Warnings on Sleep-Disordered Breathing
Prescription testosterone packaging carries explicit warnings regarding the potential potentiation of sleep apnea.
In section 5.10 of the official package insert for AZMIRO, the manufacturer states that testosterone products may potentiate sleep apnea in some patients. The warning highlights individuals with specific risk factors such as obesity or chronic lung diseases. Section 5.1 adds that increases in hematocrit levels reflecting expansions in red blood cell mass may require discontinuing the medication.
Topical formulations contain comparable statutory warnings. The prescribing information for Testim 1% testosterone gel states that treatment may potentiate sleep apnea in vulnerable men. In its clinical adverse reactions section, 2.8% of patients in the 100 mg dose group developed a hematocrit at or above 58%. Another 2.3% showed hemoglobin increases reaching 19 gm/dL or higher.
Older generic labeling establishes periodic blood surveillance as a baseline safety measure. The generic testosterone cypionate package insert instructs clinicians to check hemoglobin and hematocrit periodically during long-term therapy. These mandatory package warnings reflect regulatory caution rather than randomized trial proof of widespread airway collapse. Reviewing TRT side effects and risks helps you track the specific parameters your clinician monitors.
Cardiovascular Findings and Evidence Limits in the TRAVERSE Trial
The largest modern safety trial of testosterone therapy demonstrated cardiovascular noninferiority, but it tracked zero sleep-disordered breathing outcomes.
Published in The New England Journal of Medicine, the TRAVERSE trial investigated 5,246 men aged 45 to 80. Participants had clinical hypogonadism and preexisting cardiovascular disease or elevated cardiovascular risk. Lincoff and colleagues randomised men to daily transdermal 1.62% testosterone gel or placebo. Mean treatment duration lasted 21.7 months, with an average follow-up of 33.0 months.
Primary major adverse cardiovascular events occurred in 182 patients (7.0%) on testosterone and 190 (7.3%) on placebo. Testosterone proved noninferior, showing a hazard ratio of 0.96 (P<0.001). However, secondary safety analysis revealed higher rates of atrial fibrillation (3.5% versus 2.4%, P=0.02) and pulmonary embolism (0.9% versus 0.5%). Acute kidney injury appeared in 2.3% of testosterone participants against 1.5% on placebo. The trial collected no polysomnography data and reported no sleep-apnea endpoint. TRAVERSE cannot answer whether testosterone alters airway stability during sleep.
The longest trial with polysomnography endpoints ran 18 weeks. This evidence does not apply to men managing untreated severe obstructive sleep apnea, who fall under professional guideline contraindications. What would change our answer is a randomised trial comparing polysomnography-measured AHI changes across different testosterone formulations over a full year. If you suspect nighttime breathing interruptions, your physician can order a sleep study that measures your apnea-hypopnea index. The guideline restriction on TRT and sleep apnea applies only above 30 events per hour.
Frequently Asked Questions
Does TRT cause sleep apnea?
Testosterone replacement therapy has not been proven to cause de novo obstructive sleep apnea in healthy adult men. In a randomised trial published in Clinical Endocrinology, Hoyos and colleagues observed that testosterone undecanoate worsened overnight oxygen desaturation at 7 weeks, but this difference vanished by week 18. Furthermore, Killick and colleagues found no alteration in awake ventilatory chemoreflexes over 18 weeks. While Liu and colleagues observed increased respiratory disturbance events in 17 men over 60 receiving weekly injections, acoustic reflectometry confirmed no narrowing of the upper airway. Large meta-analyses, such as the 19-trial review by Calof and colleagues, found no statistically significant difference in sleep apnea diagnoses between testosterone and placebo groups. Prescribing labels warn of potential potentiation, but clinical trials do not show that testosterone creates anatomical airway obstruction where none previously existed.
Does TRT make existing sleep apnea worse?
Clinical evidence indicates that testosterone can temporarily worsen oxygen desaturation in men with preexisting severe obstructive sleep apnea. In the 18-week trial conducted by Hoyos and colleagues, men with severe apnea receiving intramuscular testosterone undecanoate experienced an additional 10.3 oxygen desaturation events per hour at week 7 compared to placebo. Time spent below 90% oxygen saturation also rose by 6.1%. However, by week 18, this early disparity resolved, with no significant differences remaining between the testosterone and placebo groups for either measure. The investigators concluded that testosterone produces a mild, time-limited exacerbation rather than permanent respiratory decline. Separately, the Endocrine Society guideline advises against initiating testosterone therapy in men with untreated severe obstructive sleep apnea. Mild and moderate cases were not included in that guideline restriction.
Should I get a sleep study before starting TRT?
Clinical practice guidelines from the Endocrine Society advise against initiating testosterone therapy in men with untreated severe obstructive sleep apnea, making objective diagnosis relevant if you experience sleep symptoms. A diagnostic sleep study measures your apnea-hypopnea index (AHI) to determine whether breathing pauses exceed 30 events per hour of sleep. Home sleep apnea testing provides a convenient option, but research in the Journal of Clinical Sleep Medicine shows that home monitors can underestimate apnea severity by an average of 23% compared to home polysomnography. This underestimation occurs because home devices calculate event frequency against total recording time rather than actual sleep duration. If you report frequent nighttime gasping, heavy snoring, or excessive daytime exhaustion, your physician may order a sleep evaluation to confirm your airway status before prescribing hormone therapy.
Does treating sleep apnea raise testosterone?
Treating obstructive sleep apnea with airway therapy does not reliably increase circulating testosterone levels in clinical trials. A 2022 meta-analysis in Andrology confirmed that men with severe apnea have significantly lower testosterone than healthy controls, even after adjusting for age and body mass index. However, reversing nocturnal airway collapse does not stimulate testicular hormone production. In a systematic review published in the Journal of Clinical Sleep Medicine, Cignarelli and colleagues evaluated 12 studies and found that continuous positive airway pressure (CPAP) produced no significant change in total testosterone levels (P=0.18). A separate meta-analysis by Zhang and colleagues in PLOS ONE analyzed 232 men and similarly found no change after CPAP therapy. While airway treatment resolves nighttime hypoxemia and daytime somnolence, it does not restore endocrine function.
Does CPAP increase testosterone levels?
Continuous positive airway pressure (CPAP) does not meaningfully increase total testosterone levels according to published meta-analyses. In a systematic review by Cignarelli and colleagues involving 388 patients across 12 clinical studies, CPAP therapy produced a statistically non-significant mean difference in total testosterone of 1.08 (P=0.18). The authors concluded that their findings do not support a direct physiological interaction where relieving nighttime airway obstruction restores normal endocrine output. Similarly, a meta-analysis by Zhang and colleagues in PLOS ONE evaluating 7 clinical studies found no significant change in testosterone concentrations before and after CPAP use (P=0.558). While CPAP remains the primary medical standard for stabilizing the nocturnal airway and reducing hypoxemia, individuals with confirmed hypogonadism generally require distinct medical management to normalize their circulating androgen levels.
Why does TRT raise hematocrit, and what does that have to do with apnea?
Testosterone stimulates bone marrow erythropoiesis by enhancing production of erythropoietic stimulation factor, leading to an increase in circulating red blood cell mass. In a meta-analysis of 19 randomised trials by Calof and colleagues, men on testosterone were nearly four times as likely to develop a hematocrit above 50% compared to placebo. Obstructive sleep apnea also stimulates red blood cell production because nocturnal oxygen desaturations trigger intermittent systemic hypoxemia. While both conditions independently raise hematocrit, no clinical trial has quantified their combined additive risk in a dedicated patient arm. To manage this marker safely, the Endocrine Society guideline advises clinicians to check hematocrit at baseline and at 3 to 12 months, and to withhold testosterone if hematocrit exceeds 54% until levels normalize, resuming at a lower dose.
Which form of testosterone raises hematocrit the most?
Oral testosterone undecanoate and short-acting intramuscular injections produced the largest mean hematocrit increases among the studied formulations. A 2022 Bayesian network meta-analysis published in The Journal of Urology evaluated 29 randomised trials involving 3,393 men. Intramuscular testosterone enanthate and cypionate produced a mean hematocrit increase of 4.0% compared to placebo, while oral testosterone undecanoate generated a 4.3% increase. Transdermal gels caused a 3.0% rise, long-acting intramuscular undecanoate produced a 1.6% rise, and transdermal patches generated the smallest increase at 1.4%. The analysis confirmed that short-acting injections raise hematocrit significantly more than transdermal patches. However, these trials evaluated general hypogonadal men and did not specifically recruit patients with sleep-disordered breathing, so formulation rankings describe general erythrocytosis rather than sleep-apnea-specific outcomes.
What AHI counts as severe sleep apnea?
The American Academy of Sleep Medicine classifies obstructive sleep apnea severity using the apnea-hypopnea index (AHI), which tallies total apneas and hypopneas per hour of recorded sleep. An AHI below 5 events per hour is considered normal. Mild sleep apnea is diagnosed between 5 and 15 events per hour. Moderate sleep apnea spans 15 to 30 events per hour. Severe sleep apnea is diagnosed when the index exceeds 30 events per hour of sleep. This severe threshold of 30 events is clinically critical because the Endocrine Society clinical guideline explicitly recommends against initiating testosterone therapy in men with untreated severe obstructive sleep apnea. The guideline does not name mild or moderate sleep apnea in that restriction, so it applies only above 30 events per hour.